📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-25 17:40
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Transpek Reports Q1 Revenue of ₹155.1 Cr (-6.5% YoY); Outlines R&D and Odisha Expansion Plans
Transpek Industry reported Q1 FY27 revenue of ₹155.1 crore, down 6.5% YoY amid subdued global demand and pricing competition. International business contributed 84.4% of total revenue, with polymer applications accounting for 48.7% and specialty chemicals at 22.5%. The company is doubling its R&D team this fiscal year, building a 4-stream multipurpose pilot plant over the next 6-7 months, and preparing a feasibility report to acquire land in Odisha. With near-zero debt (D/E 0.08) and ₹768 crore in net worth, management plans to fund these value-added chemistry initiatives via internal accruals.
Confidence: HIGH
What changedSubmission of the transcript for the investor/business update call held on August 20, 2026.
Why it mattersProvides operational insight into Transpek's pivot toward high-margin complex chemistries (polymers, modifiers, chloro-fluoro intermediates) to mitigate commodity pricing volatility.
Q1 FY27 Revenue: ₹155.1 crYoY Revenue Change: -6.5%Exports Revenue Share: 84.4%Polymer End-user Mix: 48.7%Pilot Plant Setup Timeline: 6-7 months
📅 Short termPerformance may remain subdued over upcoming quarters given ongoing macro headwinds in Europe and China alongside elevated freight and pricing pressures.
📈 Long termTransition from traditional acid/alkyl chlorides to specialized multi-step polymers and fluoro-compounds could enhance operating margins and reduce client/product concentration over the medium term.
⚠ Risk flags
- High geographical concentration with 84.4% export dependency exposed to global shipping and trade disruptions.
- Competitive pricing pressure in core chlorination chemistries.
- Long lead times associated with commercial validation of high-end polymer and modifier chemistries.
Key Highlights
Q1 FY27 revenue stood at ₹155.1 crore, down 6.5% YoY due to aggressive pricing and soft export demand.
International markets accounted for 84.4% of quarterly revenues, led by North America.
Polymers represented 48.7% of revenues, followed by specialty chemicals at 22.5% and pharmaceuticals at 10.11%.
Setting up a 4-stream multi-purpose pilot plant within 6-7 months and doubling R&D talent and infrastructure in FY27.
Pursuing land acquisition in a notified zone in Odisha; detailed feasibility study underway prior to board approval.
👀 What to Watch
Track progress on the multi-purpose pilot plant over the next 6-7 months and monitor board approvals regarding the proposed Odisha facility.
Transpek Industry Approves Q1 FY27 Unaudited Financial Results
Transpek Industry's Board of Directors met on August 7, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This follows a trailing twelve-month (TTM) period where the company generated Rs 621 Cr in revenue and Rs 46 Cr in PAT. The company currently maintains a low debt-to-equity ratio of 0.08 and a market capitalization of Rs 740 Cr. Investors should note the trading window is scheduled to re-open on August 10, 2026.
Confidence: HIGH
What changedThe company has formally approved and released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersAs a small-cap commodity chemical player, quarterly results are the primary indicator of how global chemical pricing and demand cycles are impacting the company's 15% operating margins.
TTM Revenue: Rs 621 CrTTM PAT: Rs 46 CrDebt-to-Equity: 0.08Market Cap: Rs 740 CrBoard Meeting Date: August 7, 2026
📅 Short termThe stock may see volatility in the coming days as the market digests the specific growth or contraction in the Q1 numbers relative to the previous quarter's Rs 148.22 Cr revenue.
📈 Long termLimited structural impact unless the results indicate a significant shift in the company's 8% ROCE or a major change in the commodity chemical cycle.
Key Highlights
Board meeting held on August 7, 2026, to approve Q1 FY27 financial results
Trading window for insiders to re-open on August 10, 2026
TTM revenue stands at Rs 621 Cr with an operating profit margin of 15.0%
Company maintains a low debt profile with total debt of Rs 60 Cr against a net worth of Rs 768 Cr
👀 What to Watch
Investors should examine the full financial tables to compare Q1 FY27 revenue and margins against the Q1 FY26 revenue of Rs 154.23 Cr and PAT of Rs 15.58 Cr to assess growth momentum.
